Understanding rare gynecologic cancers through genetic analysis
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is collecting tissue and blood samples from people with rare gynecologic cancers (like certain ovarian tumors, uterine sarcomas, and vulvar cancer) to understand their genetic makeup. The goal is to find better ways to manage and treat these rare cancers in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a confirmed diagnosis of one of these rare cancers: non-epithelial ovarian tumor (a rare type of ovarian cancer), uterine sarcoma (a rare cancer of the womb's muscle or connective tissue), or vulvar cancer
- You do not have an active HIV, hepatitis B, or hepatitis C infection
- You have no other cancer diagnosed at the same time (no synchronous neoplasm)
- You do not have a common (non-rare) gynecologic cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at very rare types of female reproductive system tumors. It collects tissue samples to better understand these cancers. You may join if you have one of these rare tumors and have had surgery.
This study is looking at people with rare cancers affecting the female reproductive system. It may help researchers learn more about how these cancers behave and how best to follow patients over time.
This study looks at tumor tissue and blood samples to find biological “markers” in people with gynecologic cancers. It may help researchers understand disease better and could guide future, more personalized treatments.
This study looks at the genetic information (DNA) from your blood and from saved tumor tissue to better understand certain cancers, especially rare cancers with a poor outlook. It may help researchers learn why these cancers behave the way they do and guide future treatments.
This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.
This study tests a new approach called SmartMatch that looks at the unique traits of your tumor to find the best treatment for you. The goal is to see if this personalized approach is feasible and helpful for people with rare gynecologic cancers.
Hear when a new Uterine Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.